Glucose Control and Continuous Glucose Monitoring Metrics During 12 Months of Treatment with Tirzepatide in Overweight or Obese Patients with Type 1 Diabetes.

Key Result

Adjunctive tirzepatide treatment in overweight or obese adults with type 1 diabetes improved CGM metrics over 12 months without increasing hypoglycemia risk.

Key Points

• To evaluate the effects of tirzepatide on glucose control metrics in overweight or obese individuals with type 1 diabetes over 12 months.
• Real-world observational study design
• Participants included adults with type 1 diabetes
• Tirzepatide was administered as adjunctive treatment
• Continuous glucose monitoring metrics were assessed over 12 months
• Sustained improvements in continuous glucose monitoring metrics were observed
• No increased risk of hypoglycemia linked to tirzepatide treatment
• Findings indicate the potential effectiveness of tirzepatide for glucose control in this population